Overview

A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Please note this study is not being conducted in the United States. The purpose of this study is to assess the acute effects of vildagliptin, an unapproved drug, in reducing post-meal glucose levels by delaying gastric emptying.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Vildagliptin